Literature DB >> 20975808

Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

Sylvia H Jackson, Tonya S Martin, Jocelyn D Jones, David Seal, Frank Emanuel.   

Abstract

Entities:  

Year:  2010        PMID： 20975808      PMCID： PMC2957743     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  25 in total

1.  Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Authors:  P J Larsen; C Fledelius; L B Knudsen; M Tang-Christensen
Journal:  Diabetes       Date:  2001-11       Impact factor: 9.461

2.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

Authors:  H Agersø; L B Jensen; B Elbrønd; P Rolan; M Zdravkovic
Journal:  Diabetologia       Date:  2002-02       Impact factor: 10.122

3.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Authors:  John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

4.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Authors:  Helena W Rodbard; Paul S Jellinger; Jaime A Davidson; Daniel Einhorn; Alan J Garber; George Grunberger; Yehuda Handelsman; Edward S Horton; Harold Lebovitz; Philip Levy; Etie S Moghissi; Stanley S Schwartz
Journal:  Endocr Pract       Date:  2009 Sep-Oct       Impact factor: 3.443

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors:  D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal:  Diabetologia       Date:  2009-08-14       Impact factor: 10.122

10.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152
View more
  9 in total

Review 1.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

2.  Synthesis and biological evaluation of S-lipidated lipopeptides of a connexin 43 channel inhibitory peptide.

Authors:  Sung-Hyun Yang; Connor A Clemett; Margaret A Brimble; Simon J O'Carroll; Paul W R Harris
Journal:  RSC Med Chem       Date:  2020-07-10

Review 3.  Catalysts for the Enzymatic Lipidation of Peptides.

Authors:  Yiwu Zheng; Ying Cong; Eric W Schmidt; Satish K Nair
Journal:  Acc Chem Res       Date:  2022-04-20       Impact factor: 24.466

Review 4.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Authors:  Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva
Journal:  Cardiovasc Diabetol       Date:  2018-12-13       Impact factor: 9.951

5.  Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.

Authors:  Jeff Unger; Dale C Allison; Melissa Carlton; Kavitha Lakkole; Derek Lowe; Gerri Murphy; Jayant K Panda; Mehmet Sargin; Margit Kaltoft; Marianne B Treppendahl; Marouan Zoghbi
Journal:  Diabetes Obes Metab       Date:  2019-03-26       Impact factor: 6.577

Review 6.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  Effects of liraglutide on sperm characteristics and fertilization potential following experimentally induced diabetes in mice.

Authors:  Maryam Pourheydar; Shapour Hasanzadeh; Mazdak Razi; Bagher Pourheydar; Gholamreza Najafi
Journal:  Vet Res Forum       Date:  2021-03-15       Impact factor: 1.054

8.  Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis.

Authors:  Tea Omanovic Kolaric; Tomislav Kizivat; Vjera Mihaljevic; Milorad Zjalic; Ines Bilic-Curcic; Lucija Kuna; Robert Smolic; Aleksandar Vcev; George Y Wu; Martina Smolic
Journal:  Curr Issues Mol Biol       Date:  2022-08-02       Impact factor: 2.976

9.  Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shinje Moon; Jibeom Lee; Hye Soo Chung; Yoon Jung Kim; Jae Myung Yu; Sung Hoon Yu; Chang-Myung Oh
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.